Niuansas, MB - financials and debts

Company age: 4 y. 5 mo.

Update

Niuansas - Company finances

EUR
2022
From: 2022-05-06
To: 2022-12-31
2023
From: 2023-01-01
To: 2023-12-31
2024
From: 2024-01-01
To: 2024-12-31
2025
From: 2025-01-01
To: 2025-12-31
Financial data
Sales revenue 17,252 74,108 72,592 76,975
Profit before tax - - - -
Net profit 3,731 27,312 16,560 1,216
Equity 3,731 32,481 47,971 49,181
Liabilities 14,229 4,138 211,938 196,065
Non-current assets 0 0 248,332 217,082
Current assets 17,960 36,619 11,577 28,164
Total assets 17,960 36,619 259,909 245,246
Taxes paid
STI taxes - 29 1,513 922
Financial indicators
Revenue change y/y - +329.6% -2.0% +6.0%
ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. 20.8% 74.6% 6.4% 0.5%
ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. 100.0% 84.1% 34.5% 2.5%
Profit margin Net profit margin. Shows the overall profitability of the company. 21.6% 36.9% 22.8% 1.6%
EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. - - - -
Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. 3.8 0.1 4.4 4.0
Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. - - - -

Purchase full financial statements

Profit/Loss, Balance Sheet, Cash Flow, Equity

9.99 € + PVM Buy

See Scoris data in Google Search

Mark Scoris as a favorite source. One click, no registration.

Niuansas - Social security debts

From To Debt, €
2025-11-01 2025-11-30 72.45

Niuansas - VMI tax arrears

From To Overdue, €
2026-02-21 2026-03-08 0.21
2024-07-01 2025-04-16 3.96

VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.

Analysis of the company's financial position

This description was generated by artificial intelligence. Report if inaccurate.
Niuansas, MB (company code 306075557) is a small partnership engaged in beauty care and other beauty treatment activities. In the latest financial year, 2025, the company generated revenue of €77.0K, up 6.0% year on year and 3.9% over two years. Net profit decreased to €1.2K, resulting in a margin of 1.6%, compared with €16.6K in 2024 and €27.3K in 2023. This shows that turnover remained broadly stable, while profitability weakened markedly in 2025. The balance sheet remained sizable for the business: total assets stood at €245.2K, equity at €49.2K and liabilities at €196.1K. Asset turnover was 0.31x, ROE was 2.5% and ROA was 0.5%. The debt-to-equity ratio of 3.99 indicates a materially leveraged capital structure. Over the three-year period, revenue fluctuated within a narrow range, whereas profit trended down and the asset base stayed elevated after the sharp increase recorded in 2024.